Ardelyx(US:ARDX)2023-03-02 21:30IBSRELA (Tenapanor) for IBS-C - IBSRELA is a first-in-class therapy for Irritable Bowel Syndrome with Constipation (IBS-C) in adults, indicated at 50 mg BID[8, 28] - In clinical trials, diarrhea was a common adverse reaction, occurring in 16% of IBSRELA-treated patients versus 4% in the placebo group[7, 32] - A Spherix survey reported that 60% of surveyed GIs have adopted IBSRELA[13] - IBSRELA recorded $15.6 million in net sales since launch in March 2022 (as of Dec 31, 2022)[19, 39] - The U S IBS-C market has 5 2 million prescriptions for indicated products in 2022[22, 34] and $3 1 billion in sales[24] XPHOZAH (Tenapanor) for Hyperphosphatemia - XPHOZAH is an investigational, first-in-class phosphate absorption inhibitor for hyperphosphatemia treatment, pending FDA review[42] - In clinical trials, diarrhea (47%) was the most common adverse reaction reported in XPHOZAH-treated patients[54] - A Spherix survey reported that 72% of nephrologists reported a high interest in XPHOZAH[59] - Approximately 80% of over 550,000 U S patients with CKD on dialysis require Rx treatment for hyperphosphatemia[42, 45] Corporate Strategy and Financials - Ardelyx is focused on developing and commercializing therapies for unmet needs in established therapeutic areas[15, 74] - Ardelyx had $123.9 million in cash and investments as of December 31, 2022[69]